June 1, 2021
AstraZeneca said on May 31 that it has filed a new drug application in Japan for its antibody drug tezepelumab for the treatment of severe uncontrolled asthma. Tezepelumab is a potential first-in-class antibody that inhibits the action of TSLP, a...read more